Development of PI3K inhibitors: Advances in clinical trials and new strategies (Review)
Dandan Meng, Wei He, Yan Zhang, Zhenguo Liang, Jinling Zheng, Xu Zhang, Xing Zheng, Peng Zhan, Hongfei Chen, Wen-Jun Li, Lintao Cai
Topics & Concepts
IdelalisibPI3K/AKT/mTOR pathwayChronic lymphocytic leukemiaMedicineClinical trialProtein kinase BPharmacologyCancer researchKinaseLeukemiaSignal transductionChemistryImmunologyInternal medicineBiochemistryIbrutinibPI3K/AKT/mTOR signaling in cancerProtein Degradation and InhibitorsChronic Lymphocytic Leukemia Research